Suppr超能文献

胸腔积液和血清标志物对良恶性胸腔积液的鉴别诊断价值。

Diagnostic utility of pleural fluid and serum markers in differentiation between malignant and non-malignant pleural effusions.

机构信息

Department of Internal Medicine, Pneumology and Allergology, Medical University of Warsaw, Warsaw, Poland.

出版信息

Eur J Med Res. 2009 Dec 7;14 Suppl 4(Suppl 4):128-33. doi: 10.1186/2047-783x-14-s4-128.

Abstract

STUDY OBJECTIVE

To evaluate the diagnostic value of four different tumor markers: cancer antigen 125 (CA-125), carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA 21-1) and neuron specific enolase (NSE) in patients with malignant and non-malignant pleural effusion.

MATERIAL AND METHODS

One hundred and two patients with pleural effusion treated in the University Hospital in Warsaw between 2001 and 2003 were studied. They underwent an extensive, diagnostic work-up in order to determine the pleural effusion etiology. Patients with known pleural fluid etiology were labeled as the study group and submitted for further analysis. Pleural fluid and serum samples for CA-125, CEA, CYFRA 21-1 and NSE measurements were collected during the first thoracentesis, centrifuged, and frozen until further use. Pleural fluid and serum concentration of tumor markers were assessed by electrochemiluminescence methods using commercial kits.

RESULTS

74 patients (32 M, 42 F; mean age 65 +/-14 years) composed the final study group. Exudative pleural effusion was found in 62 patients; of these 36 were malignant (48.6% of all effusions), 20 parapneumonic (or pleural empyema), and 6 tuberculous. In 12 patients, pleural transudate was diagnosed. The highest diagnostic sensitivity for malignant pleural effusion was found for NSE (94.4% and 80.6% in the pleural fluid and serum, respectively). However, the specificity of NSE measurement was relatively low (36.1% and 47.4% in pleural fluid and serum, respectively). The most specific markers of malignant pleural fluid etiology were pleural fluid CYFRA 21-1 and CEA levels (92.1% and 92.1%, respectively). CA-125 was found to be the most specific serum marker of pleural malignancies (78.9%). The AUC for combined pleural markers was 0.89, combined serum markers 0.82, combined ratio pleural/serum markers 0.88.

CONCLUSIONS

There are significant differences between the diagnostic value of various pleural fluid and serum markers. Overall, pleural fluid markers are superior to serum markers in determining the pleural fluid etiology. A combination of two or more tumor markers may help improve their diagnostic accuracy. Pleural fluid and serum measurements of different tumor markers play a limited role in the differentiation between malignant and non-malignant pleural effusions.

摘要

研究目的

评估四种不同肿瘤标志物在恶性和非恶性胸腔积液患者中的诊断价值:癌抗原 125(CA-125)、癌胚抗原(CEA)、细胞角蛋白 19 片段(CYFRA 21-1)和神经元特异性烯醇化酶(NSE)。

材料和方法

2001 年至 2003 年期间,在华沙大学医院治疗的 102 例胸腔积液患者进行了研究。他们接受了广泛的诊断性检查,以确定胸腔积液的病因。已知胸腔液病因的患者被标记为研究组,并进行进一步分析。在第一次胸腔穿刺时收集胸腔积液和血清样本以测量 CA-125、CEA、CYFRA 21-1 和 NSE,离心并冷冻以备进一步使用。使用商业试剂盒通过电化学发光法评估胸腔积液和血清中肿瘤标志物的浓度。

结果

74 例患者(32 例男性,42 例女性;平均年龄 65 +/-14 岁)组成最终的研究组。62 例患者为渗出性胸腔积液;其中 36 例为恶性(所有胸腔积液的 48.6%),20 例为类肺炎性(或脓胸),6 例为结核性。12 例患者诊断为胸腔漏出液。NSE 对恶性胸腔积液的诊断敏感性最高(胸腔积液和血清中的分别为 94.4%和 80.6%)。然而,NSE 测量的特异性相对较低(胸腔积液和血清中的分别为 36.1%和 47.4%)。恶性胸腔积液病因的最特异标志物是胸腔积液 CYFRA 21-1 和 CEA 水平(分别为 92.1%和 92.1%)。CA-125 是胸腔恶性肿瘤最特异的血清标志物(78.9%)。联合胸腔标志物的 AUC 为 0.89,联合血清标志物为 0.82,联合胸腔/血清标志物比值为 0.88。

结论

各种胸腔积液和血清标志物的诊断价值存在显著差异。总体而言,胸腔积液标志物在确定胸腔积液病因方面优于血清标志物。两种或多种肿瘤标志物的联合使用可能有助于提高其诊断准确性。不同肿瘤标志物的胸腔积液和血清测量在区分恶性和非恶性胸腔积液方面作用有限。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bc5/3521354/f35be88a040f/2047-783X-14-S4-128-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验